Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Gains from Sales and Divestitures: 2011-2025

Historic Gains from Sales and Divestitures for Anika Therapeutics (ANIK) over the last 4 years, with Jun 2025 value amounting to $311,335.

  • Anika Therapeutics' Gains from Sales and Divestitures rose 4.27% to $311,335 in Q2 2025 from the same period last year, while for Jun 2025 it was $311,335, marking a year-over-year increase of 4.27%. This contributed to the annual value of $311,441 for FY2024, which is 18.90% up from last year.
  • Anika Therapeutics' Gains from Sales and Divestitures amounted to $311,335 in Q2 2025, which was up 24.45% from $250,172 recorded in Q1 2025.
  • Anika Therapeutics' 5-year Gains from Sales and Divestitures high stood at $311,441 for Q4 2024, and its period low was $87,953 during Q1 2022.
  • Over the past 3 years, Anika Therapeutics' median Gains from Sales and Divestitures value was $260,536 (recorded in 2023), while the average stood at $267,592.
  • Data for Anika Therapeutics' Gains from Sales and Divestitures shows a peak YoY skyrocketed of 2,150.33% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Gains from Sales and Divestitures stood at $91,680 in 2021, then surged by 79.07% to $164,167 in 2022, then soared by 59.56% to $261,939 in 2023, then increased by 18.90% to $311,441 in 2024, then grew by 4.27% to $311,335 in 2025.
  • Its Gains from Sales and Divestitures stands at $311,335 for Q2 2025, versus $250,172 for Q1 2025 and $311,441 for Q4 2024.